Sun Medilab Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 17-07-2024
- Paid Up Capital ₹ 5.90 M
as on 17-07-2024
- Company Age 17 Year, 10 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 96.76%
(FY 2020)
- Profit 141.00%
(FY 2020)
- Ebitda 35.53%
(FY 2020)
- Net Worth 10.22%
(FY 2020)
- Total Assets 10.21%
(FY 2020)
About Sun Medilab
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 5.90 M, as per Ministry of Corporate Affairs (MCA) records.
Naresh Goel, Mohit Goel, and Ramesh Goel serve as directors at the Company.
- CIN/LLPIN
U24100DL2007PTC171319
- Company No.
171319
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 2007
- Date of AGM
11 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sun Medilab?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Goel  | Director | 11-Dec-2007 | Current |
| Mohit Goel | Director | 25-Dec-2013 | Current |
| Ramesh Goel | Director | 01-Sep-2009 | Current |
Financial Performance and Corporate Structure Insights of Sun Medilab.
Sun Medilab Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 96.76% increase. The company also saw a substantial improvement in profitability, with a 141% increase in profit. The company's net worth Soared by an impressive increase of 10.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sun Medilab?
In 2020, Sun Medilab had a promoter holding of 48.31% and a public holding of 51.69%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Recova Pharma Expo Private LimitedActive 18 years 9 monthsNaresh Goel and Ramesh Goel are mutual person
Warner India Lifesciences LimitedActive 13 years 3 monthsNaresh Goel and Mohit Goel are mutual person
- Sentosa Geigy (India) Labs LimitedActive 14 years 10 months
Naresh Goel, Mohit Goel and 1 more are mutual person
- Shrish Enterprises Private LimitedActive 24 years 8 months
Naresh Goel and Ramesh Goel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sun Medilab?
Unlock and access historical data on people associated with Sun Medilab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sun Medilab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sun Medilab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
